多発性硬化症におけるインターフェロンβ:どのくらいのBENEFIT?

Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026

Same author

IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.

JAMA neurology·2026

Same author

Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

Neurologia i neurochirurgia polska·2026

Same author

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Brain : a journal of neurology·2026

Same author

Long-Term Outcomes in Stiff Person Spectrum Disorder.

European journal of neurology·2026

Same author

The cascade to pathogenicity in autoantibody-mediated CNS diseases.

Brain : a journal of neurology·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026

Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026

関連する実験動画

多発性硬化症におけるインターフェロンβ:どのくらいのBENEFIT?

関連する概念動画

Gephyrin Neurological Autoimmunity.

IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.

Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Long-Term Outcomes in Stiff Person Spectrum Disorder.

The cascade to pathogenicity in autoantibody-mediated CNS diseases.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

関連する実験動画

多発性硬化症におけるインターフェロンβ:どのくらいのBENEFIT?

関連する概念動画

関連記事

Gephyrin Neurological Autoimmunity.

IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.

Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Long-Term Outcomes in Stiff Person Spectrum Disorder.

The cascade to pathogenicity in autoantibody-mediated CNS diseases.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.